Oxford SARS CoV 2 Lecture 5
Professor Kari Nadeau is the Naddisy Foundation Endowed Professor of Medicine and Pediatrics and Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. In addition, she is the Section Chief in Asthma and Allergy in the Pulmonary, Allergy and Critical Care Division at Stanford and the Senior Director of Clinical Research for the Division of Stanford Medicine Hospitals. Throughout her career, she has been a pioneer in the field of Translational Allergy and Immunology, both defining the mechanisms of new therapies and then translating them clinically to make transformative changes in patient care. Furthermore, she has led research in oncology, transplant and autoimmune trials and is a member of the National Steering Committee for the intramural clinical research programs at the NIH. She has also started four biotech companies in the Bay Area under Stanford patents and has worked in industry to lead two drugs through the FDA to approval. During the current COVID-19 pandemic, she led one of the key successful NIH NIAID-funded Remdesivir clinical trials as a potential therapeutic for SARS-CoV-2. On April 29th, Dr. Anthony Fauci, the Director of NIH and a current member of the US Coronavirus Task Force, announced that Remdesivir will become the “new standard of care” for COVID-19.
